These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 35136963)
61. [The Efficacy of Neoadjuvant Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer]. Sano T; Takano K; Chiba N; Tomita K; Ozawa Y; Hikita K; Shimazu M; Kawachi S Gan To Kagaku Ryoho; 2015 Nov; 42(12):1488-90. PubMed ID: 26805072 [TBL] [Abstract][Full Text] [Related]
62. Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation in Localized Pancreatic Cancer: A Case-Control Matched Analysis. Chopra A; Hodges JC; Olson A; Burton S; Ellsworth SG; Bahary N; Singhi AD; Boone BA; Beane JD; Bartlett D; Lee KK; Hogg ME; Lotze MT; Paniccia A; Zeh H; Zureikat AH Ann Surg Oncol; 2021 Jul; 28(7):3779-3788. PubMed ID: 33231769 [TBL] [Abstract][Full Text] [Related]
63. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Amer AM; Zaid M; Chaudhury B; Elganainy D; Lee Y; Wilke CT; Cloyd J; Wang H; Maitra A; Wolff RA; Varadhachary G; Overman MJ; Lee JE; Fleming JB; Tzeng CW; Katz MH; Holliday EB; Krishnan S; Minsky BD; Herman JM; Taniguchi CM; Das P; Crane CH; Le O; Bhosale P; Tamm EP; Koay EJ Cancer; 2018 Apr; 124(8):1701-1709. PubMed ID: 29370450 [TBL] [Abstract][Full Text] [Related]
64. Neoadjuvant chemoradiotherapy plus postoperative adjuvant XELOX chemotherapy versus postoperative adjuvant chemotherapy with XELOX regimen for local advanced gastric cancer-A randomized, controlled study. Wang F; Qu A; Sun Y; Zhang J; Wei B; Cui Y; Liu X; Tian W; Li Y Br J Radiol; 2021 Aug; 94(1124):20201088. PubMed ID: 34260297 [TBL] [Abstract][Full Text] [Related]
65. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01). Hayashi T; Nakamura T; Kimura Y; Yoshida M; Someya M; Kawakami H; Sakuhara Y; Katoh N; Takahashi K; Ambo Y; Miura K; Motoya M; Tanaka E; Murakawa K; Yamabuki T; Yamazaki H; Katanuma A; Hirano S; Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):606-617. PubMed ID: 31306735 [TBL] [Abstract][Full Text] [Related]
66. Neoadjuvant Chemoradiation Impacts the Prognostic Effect of Surgical Margin Status in Pancreatic Adenocarcinoma. Zhang E; Wang L; Shaikh T; Handorf E; Wong JK; Hoffman JP; Reddy S; Cooper HS; Cohen SJ; Dotan E; Meyer JE Ann Surg Oncol; 2022 Jan; 29(1):354-363. PubMed ID: 34114181 [TBL] [Abstract][Full Text] [Related]
67. A Comparison Between Plastic and Metallic Biliary Stent Placement in Patients Receiving Preoperative Neoadjuvant Chemoradiotherapy for Resectable Pancreatic Cancer. Nakamura K; Sho M; Akahori T; Nagai M; Nishiwada S; Nakagawa K; Tanaka T; Kichikawa K; Tamamoto T; Hasegawa M; Mitoro A; Yoshiji H; Ikeda N World J Surg; 2019 Feb; 43(2):642-648. PubMed ID: 30298284 [TBL] [Abstract][Full Text] [Related]
68. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma. Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715 [TBL] [Abstract][Full Text] [Related]
69. Postoperative pancreatic fistulas decrease the survival of pancreatic cancer patients treated with surgery after neoadjuvant chemoradiotherapy: A retrospective analysis. Uchida Y; Masui T; Nagai K; Anazawa T; Yoshimura M; Uza N; Takaori K; Mizowaki T; Uemoto S Surg Oncol; 2020 Dec; 35():527-532. PubMed ID: 33160278 [TBL] [Abstract][Full Text] [Related]
70. The effect of the low stromal ratio induced by neoadjuvant chemotherapy on recurrence patterns in borderline resectable pancreatic ductal adenocarcinoma. Kawahara K; Takano S; Furukawa K; Takayashiki T; Kuboki S; Ohtsuka M Clin Exp Metastasis; 2022 Apr; 39(2):311-322. PubMed ID: 35000025 [TBL] [Abstract][Full Text] [Related]
71. Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer - A Matched-Pair Analysis. Timmermann L; Rosumeck N; Klein F; Pratschke J; Pelzer U; Bahra M; Malinka T Anticancer Res; 2019 Oct; 39(10):5781-5787. PubMed ID: 31570482 [TBL] [Abstract][Full Text] [Related]
72. Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival. O'Shea AE; Bohan PMK; Carpenter EL; McCarthy PM; Adams AM; Chick RC; Bader JO; Krell RW; Peoples GE; Clifton GT; Nelson DW; Vreeland TJ Ann Surg Oncol; 2022 Sep; 29(9):6015-6028. PubMed ID: 35583691 [TBL] [Abstract][Full Text] [Related]
73. Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer. Thanikachalam K; Damarla V; Seixas T; Dobrosotskaya I; Wollner I; Kwon D; Winters K; Raoufi M; Li J; Siddiqui F; Khan G Am J Clin Oncol; 2020 Jun; 43(6):435-441. PubMed ID: 32251119 [TBL] [Abstract][Full Text] [Related]
74. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data. Weyhe D; Obonyo D; Uslar VN; Stricker I; Tannapfel A PLoS One; 2021; 16(3):e0248633. PubMed ID: 33735191 [TBL] [Abstract][Full Text] [Related]
75. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis. Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208 [TBL] [Abstract][Full Text] [Related]
76. The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma undergoing pancreatectomy with combined resection of portal vein following preoperative chemoradiotherapy. Jaseanchiun W; Kato H; Hayasaki A; Fujii T; Iizawa Y; Tanemura A; Murata Y; Azumi Y; Kuriyama N; Kishiwada M; Mizuno S; Usui M; Sakurai H; Isaji S Pancreatology; 2019 Mar; 19(2):307-315. PubMed ID: 30738764 [TBL] [Abstract][Full Text] [Related]
77. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Roland CL; Yang AD; Katz MH; Chatterjee D; Wang H; Lin H; Vauthey JN; Pisters PW; Varadhachary GR; Wolff RA; Crane CH; Lee JE; Fleming JB Ann Surg Oncol; 2015 Apr; 22(4):1168-75. PubMed ID: 25352267 [TBL] [Abstract][Full Text] [Related]
78. Reduction of gender-associated M2-like tumor-associated macrophages in the tumor microenvironment of patients with pancreatic cancer after neoadjuvant chemoradiotherapy. Matsuki H; Hiroshima Y; Miyake K; Murakami T; Homma Y; Matsuyama R; Morioka D; Kurotaki D; Tamura T; Endo I J Hepatobiliary Pancreat Sci; 2021 Feb; 28(2):174-182. PubMed ID: 33316125 [TBL] [Abstract][Full Text] [Related]
79. Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. Chawla A; Qadan M; Castillo CF; Wo JY; Allen JN; Clark JW; Murphy JE; Catalano OA; Ryan DP; Ting DT; Deshpande V; Weekes CD; Parikh A; Lillemoe KD; Hong TS; Ferrone CR Ann Surg; 2022 Nov; 276(5):e502-e509. PubMed ID: 33086310 [TBL] [Abstract][Full Text] [Related]
80. Neoadjuvant therapy and major arterial resection for potentially reconstructable arterial involvement by stage 3 adenocarcinoma of the pancreas. Loveday BPT; Zilbert N; Serrano PE; Tomiyama K; Tremblay A; Fox AM; Segedi M; O'Malley M; Borgida A; Bianco T; Creighton S; Dodd A; Fraser A; Moore M; Kim J; Cleary S; Moulton CA; Greig P; Wei AC; Gallinger S; Dhani N; McGilvray ID HPB (Oxford); 2019 Jun; 21(6):643-652. PubMed ID: 30471960 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]